The advent of biological therapy has had a significant impact on the management of patients with inflammatory bowel disease. Nevertheless, anti-TNF-alpha agents are still used with caution, driven by concerns about the risk of infection. Stringent post-marketing surveillance programmes and registries have allowed early recognition of problems, highlighting an increased risk of infectious complications. Although the focus is on biological drugs, other immunomodulators have been less well scrut...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
How to manage the infectious risk under anti-TNF in inflammatory bowel disease.
Views and Downloads
If you are the owner of this record, you can report an update to it here: Report update to this record